Introduction
============

Epigenetic modifications play an important role in regulating gene expression, lifespan, and tumorigenesis. In particular, acetylation regulates a wide variety of cellular functions. Class III histone deacetylases (HDACs), also known as sirtuins, are the silent information regulator 2 (Sir2) family of proteins. Unlike other HDACs, sirtuins are NAD^+^-dependent deacetylases, not modulated by inhibitors of class I, II, and IV HDACs. The deacetylase activity of sirtuins is controlled by the cellular \[NAD^+^\]/\[NADH\] ratio, where NAD^+^ works as an activator, while nicotinamide and NADH act as inhibitors. Expressed from bacteria to humans (Vaquero, [@B33]), sirtuins seem to preferentially target non-histone proteins, although little is currently known about target specificity and selectivity. Two reactions may be catalyzed by sirtuins: deacetylation and ADP-ribosylation. In both reactions, the cleavage of NAD^+^ is the initial chemical step. Sirtuins (SirT1, SirT2, SirT3, SirT5, and SirT7) catalyze a deacetylation reaction on lysine residues of target proteins, using NAD^+^ as cofactor and releasing nicotinamide with the production of 2′-*O*-acetyl-ADP ribose. In contrast, SirT4 and SirT6 catalyze an ADP-ribosylation reaction, in which ADP-ribosyl moiety is transferred to the substrate (Yamamoto et al., [@B37]).

Catalytic Domain of Sirtuins
============================

Each member of the sirtuin family contains a highly conserved core domain consisting of an NAD^+^ binding site and a catalytic domain (Alcaín and Villalba, [@B1]). Human SirT2 consists of two globular domains: one large and one small. In the large domain, with a Rossmann fold, six β-strands form a parallel β-sheet and six α-helices. The small domain is composed of a helical and a zinc-binding module. The active site is located at the interface between the large and small domains, with a binding site for NAD^+^. The NAD^+^-binding pocket can be divided into three spatially distinct regions: the A site, with affinity for adenine--ribose, the B site, with affinity for nicotinamide--ribose, and the C site, which binds NAD^+^. In the presence of an acetyl-lysine substrate, the NAD^+^-bound B site can undergo a conformational change, bringing nicotinamide in proximity to the C site, where it can be cleaved. The ADP ribose product returns to the B site, allowing deacetylation. The C site is the binding site for free nicotinamide. At high concentrations it may occupy the site and block the conformational change of NAD^+^ (North and Verdin, [@B23]).

Sirtuin Family
==============

The mammalian sirtuin family comprises seven proteins (SirT1-7). These proteins differ in cellular localization, activity, and function, and are subdivided into four classes (Alcaín and Villalba, [@B1]; Table [1](#T1){ref-type="table"}). SirT1, the closest to yeast Sir2 in terms of sequence, is a proto-member of the family. SirT1 mediates heterochromatin formation through deacetylation of K26 on histone H1, K9 on histone H3, and K16 on histone H4. SirT1 is also involved in the deacetylation of non-histone proteins, which can be divided into three groups: (i) transcription factors (p53, FOXO, E2F1, BCL6, p73, Rb, and others); (ii) DNA repair proteins; (iii) signaling factors. Due to its ability to deacetylate a variety of substrates, SirT1 is involved in a broad range of physiological functions, including control of gene expression, metabolism, tumorigenesis, and aging.

###### 

**Diversity of human sirtuins**.

  Classes                                  Enzymatic activity                    Targets and Substrate                                                 Localization            Function                                                                                   Involvement in cancer
  --------- ------------------------------ ------------------------------------- --------------------------------------------------------------------- ----------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------
            ![](fphar-03-00004-i001.jpg)   Deacetylase                           p53, FOXO, MyoD, Ku70, [ppar]{.smallcaps}γ NFκB, PCAF, H3K9, H3KI4,   Nuclear/cytoplasmatic   Glucose metabolism, differentiation, neuroprotection, insulin secretion                    Acute myeloid leukemia, colon, bladder, prostate, glioma, nonmalignant skin, ovarian
  I         ![](fphar-03-00004-i002.jpg)   Deacetylase                           α-Tubulin FOXO                                                        Nuclear/cytoplasmatic   Cell-cycle control, tubulin deacetylation                                                  Glioma
            ![](fphar-03-00004-i003.jpg)   Deacetylase                           GHD complex 1, AceCS2                                                 Mitochondrial           ATP-production, regulation of mitochondrial proteins deacetylation, fatty-acid oxidation   Breast cancer
  II        ![](fphar-03-00004-i004.jpg)   ADP-ribosyl-transferase               GHD, ANT                                                              Mitochondrial           Insulin secretion                                                                          Breast cancer
  III       ![](fphar-03-00004-i005.jpg)   Deacetylase                           CPSI                                                                  Mitochondrial           Urea cycle                                                                                 Pancreatic, breast cancer
  IV        ![](fphar-03-00004-i006.jpg)   Deacetylase ADP-ribosyl-transferase   Hif1α, helicase NFκB, DNA polimerasi β                                Nuclear                 Telomeres and telomeric functions, DNA repair                                              Colon, breast cancer
            ![](fphar-03-00004-i007.jpg)   Deacetylase                           RNA polymerase type 1, ElA SMAD6                                      Nuclear                 RNA pol I transcription                                                                    Breast cancer

Human SirT2 co-localizes with microtubules in cytoplasm. Thus, knockdown of SirT2 results in tubulin hyperacetylation. SirT2 is also able to bind FOXO3a, reducing its acetylation levels.

SirT3 is localized in mitochondrial inner membrane, and is activated by caloric restriction. SirT4 is also mitochondrial, but no NAD^+^-dependent deacetylase activity has so far been detected for this sirtuin. SirT4 uses NAD^+^ for ADP-ribosylation of glutamate dehydrogenase, resulting in inhibition of insulin secretion and enzymatic activity of β-cells. The third mitochondrial sirtuin, SirT5, is localized in the inter-membrane space and can deacetylate cytochrome c. The last two sirtuins, SirT6 and SirT7, have recently been characterized. SirT6 exerts an NAD^+^-dependent histone H3 K9 deacetylase action able to modulate telomeric chromatin functions (Alcaín and Villalba, [@B1]). SirT6 has a role in genome stability. In mammalian cells subjected to oxidative stress, SirT6 is recruited on DNA double-strand breaks (DSB) and stimulates repair through both homologous and non-homologous end-joining recombination. Moreover, some results indicate that SirT6 is physically associated with poly \[adenosine diphosphate (ADP)-ribose\] polymerase 1 (PARP1). The amount of SirT6--PARP1 complexes increase after DNA damage. PARP1 is mono-ADP-ribosylated on lysine residue K521, thus increasing PARP1 activity and enhancing DSB repair under oxidative stress (Mao et al., [@B19]). SirT7 is a predominantly nucleolar protein associated with active rRNA genes (rDNA), where it interacts with RNA polymerase I and histones (Alcaín and Villalba, [@B1]). SirT7 does not seem to have any NAD^+^-dependent activity. Other functional characteristics of SirT6 and SirT7 remain to be further elucidated.

Some sirtuins may relocalize depending on cell or tissue type, developmental stage, stress condition, and metabolic status, suggesting that their localization is important for regulating function (McGuinness et al., [@B20]).

Sirtuins and Genome Stability
=============================

Some sirtuins (SirT1, 2, 3, 6) are linked to chromatin regulation, as they are responsible for the regulation of two histone post-translational modifications crucial for chromatin structure: acetylation of K16 and K9 on histone H4 and H3 respectively (McGuinness et al., [@B20]).

SirT1 is responsible for heterochromatin formation by a deacetylation process. Histone deacetylation can in turn facilitate histone methylation, thus enhancing global transcriptional repression. SirT1 has no effect on H3K4 methylation (a marker of open chromatin) and promotes H3K9 tri-methylation through its involvement with the histone methyltransferase Suv39H1 (Liu et al., [@B18]; Bosch-Presegue and Vaquero, [@B6]).

SirT2 and SirT3 are responsible for regulation of H4K16 acetylation. Deacetylation occurs specifically during cell-cycle in G2/M transition, in particular when SirT2 is shuttled to the nucleus (Shogren-Knaak et al., [@B29]). The mechanism of SirT3 is more complex. Although SirT3 is localized in mitochondria, its feeble nuclear expression is probably responsible for deacetylation of H4K16ac and H3K9ac in some settings (McGuinness et al., [@B20]). The finding that SirT3 knockdown does not lead to global H4K16 hyperacetylation suggests that its action occurs in limited regions of the genome.

Recently, SirT6 has been attributed with deacetylase activity (McGuinness et al., [@B20]), since it modulates acetylation of K9 and K56 on histone H3.

Sirtuins and Cancer
===================

Interest in sirtuins has grown in the last decade, mainly because of their critical role in different biological processes, such as regulation of gene expression, control of metabolic processes, apoptosis and cell survival, DNA repair, development, neuro-protection, and inflammation. Sirtuins control many vital functions and are involved in several pathologies such as metabolic diseases, neurodegenerative disorders, and cancer.

SirT1 has been shown to be significantly up-regulated in different types of cancer including acute myeloid leukemia (AML), prostate, colon, and skin cancers.

Given that only SirT1 and SirT2 seem to control levels of H4K16 acetylation in many settings, and that only SirT1 is proven to be altered in certain cancers, H4K16ac loss in cancer has been correlated with SirT1 deregulated activity.

Nevertheless, SirT1 seems to play contradictory roles, both as tumor suppressor or tumor promoter (Deng, [@B9]; Bosch-Presegue and Vaquero, [@B6]). The initial evidence that SirT1 acts as tumor promoter derives from its repressive effect on tumor suppressor p53 (Deng, [@B9]). By interacting physically with p53, SirT1 blocks its functions through deacetylation at the C-terminal K382 residue (Vaziri et al., [@B34]). Moreover, SirT1 overexpression in cancer represses p53-dependent cell-cycle arrest and apoptosis in response to DNA damage and oxidative stress. DNA damage-induced acetylation of p53 leads to its activation. In response to damage, SirT1 binds to and deacetylates p53, thus reducing its functional and transcriptional activities. Overexpression of SirT1 disrupts p53-dependent pathways, resulting in a significant reduction in the cell's ability to respond to stress and DNA damage. In contrast, the inhibition of SirT1 potentiates p53-dependent apoptosis (Deng, [@B9]; Rahman and Islam, [@B27]). These findings underline the involvement of SirT1 in tumorigenesis, given that SirT1 overexpression may increase the risk of cancer in mammals by inhibiting p53 and potentially other tumor suppressor genes, including FOXO family members, p73, Rb, and several others.

In contrast, several studies have suggested that SirT1 also has a tumor suppressor role. Decreased SirT1 levels have been reported for glioma, bladder, prostate, and ovarian cancers. Furthermore, some studies have suggested that SirT1 overexpression in APC^−/+^ mice reduces rather than increases colon cancer formation (Firestein et al., [@B10]). This action seems to be caused by SirT1 deacetylation of β-catenin, which promotes cytoplasmic localization of the nuclear-localized oncogenic form of β-catenin. In addition, in SirT1-deficient mice, embryos die at middle gestation stages, displaying increased acetylation of H3K9 and H4K16, reduced chromosome condensation and aberrant mitosis (Firestein et al., [@B10]; Deng, [@B9]). SirT1 deficiency also causes reduced DNA double-strand break repair and radiation sensitivity (Wang et al., [@B35]). It has also been suggested that SirT1 plays a role as tumor suppressor by regulating c-Myc. c-Myc binds to and induces SirT1. This interaction results in decreased c-Myc stability, compromising its transformational capability. These data provide strong evidence for a tumor suppressor role of SirT1 in these settings. Importantly, it still seems possible that the expression level and activity of SirT1 may modulate a delicate balance between suppression and promotion of oncogenesis, thus displaying dual dependence on its spatial and temporal distribution and stage of tumorigenesis (Bosch-Presegue and Vaquero, [@B6]). A potential tumor suppressor role has also been proposed for the other human sirtuins (McGuinness et al., [@B20]). This hypothesis is supported by several findings such as the reduction of SirT2 in a large number of human brain tumor cell lines, and its involvement in cell-cycle progression. SirT3 is the only mitochondrial sirtuin implicated in tumorigenesis. Its reduction in several cancers leads to an increase in ROS (reactive oxygen species) production, which results in enhanced tumor growth (Kim et al., [@B14]). SirT5 overexpression has been found in a study of pancreatic cancer (Ouaïssi et al., [@B24]). Recently, a role for SirT6 and SirT7 in tumorigenesis has also been proposed. SirT6 might be involved as a result of its control of the NFκB pathway and DNA double-strand repair. SirT7, whose expression inversely correlates with the tumorigenic potential in several murine cell lines (Vakhrusheva et al., [@B32]), displays increased expression levels in breast cancer (Ashraf et al., [@B3]).

Following these rationals, tumors with deregulated expression or function of sirtuins may benefit from an approach based on the use of SirT inhibitors.

Sirtuin and Aging Diseases
==========================

Sirtuins are believed to be involved in metabolic diseases, neurodegeneration, and aging.

It is well known that overexpression of Sir2 (or its orthologs) can extend organism lifespan in a wide range of lower eukaryotes (Bosch-Presegue and Vaquero, [@B6]). Sir2 function is often correlated to caloric restriction. The link between the role of sirtuins, caloric restriction, and longevity was first described in *S. cerevisiae*. In yeast, caloric restriction leads to increased replicative lifespan. Lifespan extension has not been observed in yeast lacking Sir2 (Lin et al., [@B17]). Currently, the role of sirtuins in the regulation of mammalian lifespan is still unclear. However, considering that sirtuins are an evolutionary conserved family of proteins, it is fair to speculate on their role in the modulation of aging-related processes in higher organisms (Westphal et al., [@B36]; Brooks and How, [@B7]). In humans, the aging process is associated with telomere erosion. SirT1 and SirT6 have a role in both the maintenance of telomeres and their function, as well as the aging process. Recent studies have demonstrated that reduction or removal of SirT6 results in telomere dysfunction and end-to-end chromosomal fusions. Symptoms displayed in the absence of SirT6 are similar to those caused by a premature aging disease, known as Werner's syndrome. To date, little is known about other sirtuins, but no evidence suggests their involvement with telomere function, formation, and stability (Westphal et al., [@B36]; McGuinness et al., [@B20]). Recently, SirT1 has been shown to promote replicative senescence in response to chronic oxidative stress, by upregulation of the p19^ARF^ senescence regulator, which in turn positively regulates p53 via inhibition of MDM2, a protein mediating p53 degradation (Chua et al., [@B8]). This effect seems to be in contrast to Sir2 function in yeast, which extends replicative lifespan.

Many studies have demonstrated that the pathogenesis of neurodegenerative diseases includes broad changes and involvement of multiple biochemical pathways. Sirtuins play a critical role in several models of neurodegenerative diseases. Many reports support the role of SirT1 in axonal protection from damage in animal models of Wallerian degenerative disease (Parkinson's disease; Araki et al., [@B2]; McGuinness et al., [@B20]; Rahman and Islam, [@B27]). SirT1 overexpression also protects against Alzheimer's and Huntington's disease as well as amyotrophic lateral sclerosis. In models of Huntington's disease, SirT1 activation reduces cell death by inhibition of NFκB signaling. Alzheimer's disease is also related to sirtuin action given that SirT1 overexpression in the brain of mice reduces β-Amyloid production and the formation of plaques. The β-Amyloid peptide generates protein aggregates (plaques) in the brain of patients (Outiero et al., [@B26]). Recent studies also suggest that SirT1 may benefit learning and memory by activating the gene for brain-derived neurotrophic factor (Gao et al., [@B11]).

Sirtuin Modulators
==================

Sirtuins play a key role in several pathologies. Recently, a great deal of research interest has been focused on the identification of small chemical compounds that modulate these proteins. To date, many inhibitors of sirtuins have been proposed for therapy against neurodegenerative diseases and cancer (Alcaín and Villalba, [@B1]). In recent years a number of inhibitors have been discovered and characterized. In addition to nicotinamide, the physiologic sirtuin inhibitor, some specific inhibitors have been proposed, including splitomicin and its analogs, tenovins, AGK2, sirtinol, suramin, the indole derivative EX-257, cambinol, salermide, and UVI5008 (Table [2](#T2){ref-type="table"}).

###### 

**Sirtuin modulators**.

  Structure                      Name           Target
  ------------------------------ -------------- -----------
  ![](fphar-03-00004-i008.jpg)   Nicotinamide   SirT1-2
  ![](fphar-03-00004-i009.jpg)   AGK2           SirT2
  ![](fphar-03-00004-i010.jpg)   Cambinol       SirT1-2
  ![](fphar-03-00004-i011.jpg)   Salermide      SirT1-2
  ![](fphar-03-00004-i012.jpg)   EX-527         SirT1
  ![](fphar-03-00004-i013.jpg)   Splitomicin    Sir2
  ![](fphar-03-00004-i014.jpg)   Suramin        SirT1-2-5
  ![](fphar-03-00004-i015.jpg)   UVI5008        SirT1-2
  ![](fphar-03-00004-i016.jpg)   Sirtinol       SirT2
  ![](fphar-03-00004-i017.jpg)   Tenovins       SirT1

Splitomicin and its derivatives were discovered in a screening for inhibitors of yeast Sir2. While splitomicin did not act very efficiently against human sirtuins, a series of its analogs with a different orientation of the β-phenyl group were developed and characterized for their activity on SirT2 (Bedalv et al., [@B4]; Neugebauer et al., [@B22]). Sirtinol is mainly an inhibitor of the yeast Sir2 and human SirT2 (Grozinger et al., [@B12]). Its inhibitory effect on growth has been described in human breast, lung, and prostate cancer cells, though using a high micromolar range.

Another potent and selective inhibitor of SirT2 is AGK2 with IC~50~ of 3.5 μM. It was demonstrated that the inhibition of SirT2 protects against dopaminergic cell death in a *Drosophila* model of Parkinson's disease (Outeiro et al., [@B25]).

Suramin is a potent inhibitor of many sirtuins: SirT1 with IC~50~ of 297 nM, SirT2 with IC~50~ of 1.15 μM, and SirT5 with IC~50~ of 22 μM. However, its reported neurotoxicity limits therapeutic use (Schuetz et al., [@B28]; Trapp et al., [@B31]).

Cambinol and salermide (Heltweg et al., [@B13]; Lara et al., [@B16]) are reported as inhibitors of SirT1 and SirT2. Cambinol shows the most potent activity against Burkitt lymphoma cell lines by a mechanism involving BCL6 acetylation. Salermide induces apoptosis in cancer cells in a p53-independent manner. The indole derivative, EX-527, is a cell-permeable, selective inhibitor of SirT1 (IC~50~ = 98 nM). Treatment with EX-527 dramatically increases acetylation at K382 of p53 after DNA damage induction in primary human mammary epithelial cells and several cell lines (Solomon et al., [@B30]). The direct interaction between SirT1 and p53 highlights potential SirT1 involvement in p53 functions, including differentiation, DNA repair, and aging. Currently, EX-527 is in phase 1 clinical trials for the treatment of Huntington's disease. In preclinical studies this inhibitor was shown to reduce neuronal death.

The only SirT inhibitors that have been tested in cancer mice models are cambinol, tenovins, and UVI5008. Tenovins, a family of small-molecule inhibitors, are able to inhibit SirT1 at single-digit micromolar concentration and prevent tumor growth *in vivo* in a p53-dependent manner as single agents. Tenovins have a potential therapeutic interest for the development of new drugs that act against tumor cells overexpressing SirT1 (Lain et al., [@B15]).

UVI5008 has recently been reported as a novel epigenetic modifier able to inhibit simultaneously histone deacetylases, sirtuins, and DNA methyltransferases. This compound induces cancer cell-selective death in several human models. Importantly, UVI5008 action is independent of p53, Bcl-2-modifying factor (BMF), and TNF-related apoptosis-inducing ligand (TRAIL), affecting the growth of tumor cells deficient or mutated for these factors. This finding potentiates its application in therapy by overcoming potential drug resistance limits. The simultaneous modulation of three classes of epigenetic enzymes offers a promising strategy for applying a single drug exerting multiple-interventions against cancer (Nebbioso et al., [@B21]).

Phenol derivates, including quercetin, piceatannol, and resveratrol, were shown to have SirT1-activating properties. The most potent activator of the three is resveratrol, a polyphenol found in grapes, and grape products. However, its activity is still debated. Given that the activation of SirT1 by resveratrol requires the use of peptides conjugated with a non-physiological fluorophore and that no activation is observed when peptides lacking this fluorophore are used, other technical approaches are necessary to establish its effective modulation of SirT1 (Borra et al., [@B5]).

Conclusion and Perspectives
===========================

Sirtuins influence several cellular processes. Growing evidence has recently underlined their involvement in many diseases. Although SirT1 has been extensively researched a better understanding of its involvement in pathogenesis is required. Many questions remain to be addressed, such as the role of the other sirtuins and their function. Further research is needed to provide clearer perspectives. The development of potent sirtuin modulators may revert the disease process and possibly extend healthy human lifespan.
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